Biotech companies partner for hepatitis therapy

Filed under: AM Roundup |

A Louisville-based company is partnering with pharmaceutical giant Gilead for a drug therapy to fight hepatitis B, says the Denver Business Journal.

GlobalImmune is developing the vaccination, and Gilead will provide the money for the first phase of clinical trials.

Read more at the Denver Business Journal.